These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38004432)

  • 1. Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database.
    Sportiello L; Di Napoli R; Balzano N; Mascolo A; Ruggiero R; Di Costanzo L; Monaco D; Maniscalco GT; Capuano A
    Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study.
    Mascolo A; di Mauro G; Fraenza F; Gaio M; Zinzi A; Pentella C; Rossi F; Capuano A; Sportiello L
    Front Immunol; 2022; 13():965171. PubMed ID: 36263025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.
    Barbieri MA; Sorbara EE; Battaglia A; Cicala G; Rizzo V; Spina E; Cutroneo PM
    Front Pharmacol; 2022; 13():808370. PubMed ID: 35281926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis.
    Porwal MH; Patel D; Maynard M; Obeidat AZ
    Mult Scler Relat Disord; 2022 Jul; 63():103832. PubMed ID: 35512502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies.
    Porwal MH; Salter A; Patel D; Obeidat AZ
    J Cent Nerv Syst Dis; 2022; 14():11795735221109674. PubMed ID: 35769950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
    di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A
    Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.
    Stamatellos VP; Siafis S; Papazisis G
    Br J Clin Pharmacol; 2021 Dec; 87(12):4769-4779. PubMed ID: 33998034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System.
    Velișcu EM; Liguori V; Anatriello A; Maniscalco GT; Cantone A; Di Costanzo L; Stefanelli P; Scavone C; Capuano A
    Pharmaceuticals (Basel); 2023 Jul; 16(8):. PubMed ID: 37630986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database.
    Rastogi S; Kalaiselvan V; Bin Jardan YA; Zameer S; Sarwat M
    Biology (Basel); 2022 Feb; 11(2):. PubMed ID: 35205206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric ADRs: A Pharmacovigilance Study Based on Data From the Italian Spontaneous Reporting System.
    Scavone C; Mascolo A; Ruggiero R; Sportiello L; Rafaniello C; Berrino L; Capuano A
    Front Pharmacol; 2020; 11():428. PubMed ID: 32351386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
    Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
    Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system.
    Scavone C; Anatriello A; Baccari I; Cantone A; Di Giulio Cesare D; Bernardi FF; Moreggia O; Liguori V; Andreone V; Maniscalco GT; Capuano A
    Front Neurol; 2024; 15():1383910. PubMed ID: 38994488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.
    Pozsgai K; Szűcs G; Kőnig-Péter A; Balázs O; Vajda P; Botz L; Vida RG
    Front Pharmacol; 2022; 13():964399. PubMed ID: 36147337
    [No Abstract]   [Full Text] [Related]  

  • 19. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.